Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer-Reference-Cited by-同舟云学术

Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer

Published:2022-04-19 Issue:6 Volume:89 Page:751-759
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Gandhi Khushboo A.,Joshi Amit,Mehta Parsshava,Gurjar Murari,Rane Pallavi,Sharma Jyoti,Patil Anand,Nookala Manjunath,Noronha Vanita,Prabhash Kumar,Gota Vikram^ORCID

Funder

Indian Council of Medical Research

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04432-4.pdf

Reference22 articles.

1. Blumenthal GM, Cortazar P, Zhang JJ et al (2012) FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17:1108–1113. https://doi.org/10.1634/THEONCOLOGIST.2012-0044

2. Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367–1373. https://doi.org/10.1158/1078-0432.CCR-06-2328

3. Bracarda S, Iacovelli R, Boni L et al (2016) Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol Off J Eur Soc Med Oncol 27:366. https://doi.org/10.1093/annonc/mdv589

4. Lee JL, Kim MK, Park I et al (2015) RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol 26:2300–2305. https://doi.org/10.1093/annonc/mdv357

5. Deng H, Li M, Wu Q et al (2020) A 2/1 sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4/2 schedule for metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Oncol. https://doi.org/10.3389/FONC.2020.00313/REFERENCE

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study;British Journal of Cancer;2024-07-06

2. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

3. Sunitinib malate induces cell death in adult human cardiac progenitor cells;Current Research in Toxicology;2024

4. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

5. An Optimized LC-MS/MS Method for Quantification of Sunitinib and N-Desethyl Sunitinib in Human Plasma and Its Application for Therapeutic Drug Monitoring;Therapeutic Drug Monitoring;2023-04-14